Ignite Creation Date:
2024-05-06 @ 9:33 AM
Last Modification Date:
2024-10-26 @ 12:16 PM
Study NCT ID:
NCT03013491
Status:
COMPLETED
Last Update Posted:
2022-02-09
First Post:
2016-12-26
Brief Title:
PROCLAIM-CX-072 A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Sponsor:
CytomX Therapeutics
Organization:
CytomX Therapeutics
Study Overview
Official Title:
An Open-Label Dose-Finding and Proof of Concept Study of the PD-L1 Probody Therapeutic CX-072 as Monotherapy and in Combination With Yervoy Ipilimumab or With Zelboraf Vemurafenib in Subjects With Advanced or Recurrent Solid Tumors or Lymphomas
Status:
COMPLETED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this first-in-human study of CX-072 is to characterize the safety tolerability pharmacokinetics PK pharmacodynamics PD and antitumor activity of CX-072 administered intravenously IV as a single agent or in combination with ipilimumab or vemurafenib in adult subjects with advanced or recurrent solid tumors or lymphomas PROCLAIM-CX-072 PRObody CLinical Assessment In Man CX-072 clinical trial
CX-072 is a Probody therapeutic directed against PD-L1 programmed cell death ligand 1 Probody therapeutics are proteolytically-activatable antibodies Abs designed to widen the therapeutic index by minimizing drug interaction with normal tissue while retaining anti-tumor activity Probody therapeutics are masked to attenuate binding to target in healthy tissue but can become unmasked in the tumor microenvironment by tumor-specific protease activity
PROBODY is a trademark of CytomX Therapeutics Inc
CX-072 is a Probody therapeutic directed against PD-L1 programmed cell death ligand 1 Probody therapeutics are proteolytically-activatable antibodies Abs designed to widen the therapeutic index by minimizing drug interaction with normal tissue while retaining anti-tumor activity Probody therapeutics are masked to attenuate binding to target in healthy tissue but can become unmasked in the tumor microenvironment by tumor-specific protease activity
PROBODY is a trademark of CytomX Therapeutics Inc
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None